A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.
about
Topical tacrolimus for atopic dermatitisNonsteroidal Topical Immunomodulators in Allergology and DermatologyThe diagnosis and graded therapy of atopic dermatitisTacrolimus ointment 0.1% in pityriasis alba: an open-label, randomized, placebo-controlled studyCost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.Atopic and non-atopic eczema.Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study).Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): General Management and Topical Treatment.Effects of oral vitamin E on treatment of atopic dermatitis: A randomized controlled trial.A systematic review of the safety of topical therapies for atopic dermatitis.The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review.The role of emollients in the management of diseases with chronic dry skin.Tacrolimus: approved and unapproved dermatologic indications/uses-physician's sequential literature survey: part II.Emerging drugs for atopic dermatitis.Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.An update on current pharmacotherapy options in atopic dermatitis.Topical corticosteroid-induced skin atrophy: a comprehensive review.Dupilumab for the treatment of atopic dermatitis: A clinical trial review.A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal.Tacrolimus ointment in the management of atopic dermatitis.Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies.Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Heal["With all suitable means". Off-label-use and public statutory employers' liability insurance].Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis.Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema.Guidelines for treatment of atopic eczema (atopic dermatitis) part I.Atopic dermatitis: a review of topical nonsteroid therapy.Topical Tacrolimus for the Treatment of Atopic Dermatitis with Truncal Lesion.Blinded side-to-side comparison of topical corticosteroid and tacrolimus ointment in children with moderate to severe atopic dermatitis
P2860
Q24186624-998F6615-E744-447A-9A78-B8E9883C2BBDQ26752832-531AAD0A-05E7-479B-A66D-BBA7F7D0C128Q27025032-3F958D75-C6EA-443B-B91B-D02C4C4A424AQ28247805-3F2DBA31-AAF7-4972-B96B-F0B9EAA9519AQ31096548-1CB7B134-BD5F-4797-99AF-2F541D1AC71DQ34441292-B92FB263-A5E4-49B5-AA08-4E872E29CB6AQ34734120-F7EBAA82-A149-4667-9B1E-4A50FF88285EQ36214247-8B5B9BCB-8EC2-4FBB-B250-FD78FD748128Q36584295-BA978244-52FE-4AC6-9C58-B2D6D91DEB9BQ36708358-8481DD0F-4F15-409E-A5FC-174B0E0AF009Q36940038-1580EECD-6C0F-44FA-AB63-FD19DF560EFAQ37054824-903A694D-EE12-46F8-ABA8-21596501F3ACQ37104570-AF7F3295-18A2-4428-A671-B9E97A8F4CBCQ37392901-F66CA6CF-7AA3-4794-BEC3-CB31E24A5A39Q37977478-9889DBD0-6802-4E00-902A-3338441A9719Q38210447-FE19F069-6AEC-4227-9433-320F4716A44FQ38415302-3311B1EA-AB5F-4EC0-A884-A97FE78B9A79Q38597397-3347177A-76F4-4435-9891-FB9188BC8228Q40068394-C4077C6A-82F5-4C34-AD4C-5CEFE713A39EQ42081579-EA35A374-5CE9-451E-85D3-84BB516E4650Q43200436-345C62C2-A087-450C-9CA3-070DF3526DFBQ44513075-58B360A2-9F96-4A37-98A3-9916F99BAECEQ45630842-9E996355-30BA-42B9-81F8-36E0197CBED5Q46641474-21CADEE5-3EEA-41C3-A06B-D9679A95B58FQ48099089-D06A90D0-E6EC-47BD-87BE-1B239D43A399Q48480285-AAE9A0D8-8BA6-4739-A1E2-F472F8832C97Q50927518-DFF5E7F0-2EE3-4175-9603-53B770787B69Q52597622-46E217CD-8E73-4AEC-AA9A-44791367F3C6Q55400196-56E5792A-9503-4040-A7EE-5633A3B4C35CQ57173891-EAC56C62-2ECA-440A-9CB1-80EB7C05DD31
P2860
A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A multicentre, randomized, dou ...... e to severe atopic dermatitis.
@en
A multicentre, randomized, dou ...... e to severe atopic dermatitis.
@nl
type
label
A multicentre, randomized, dou ...... e to severe atopic dermatitis.
@en
A multicentre, randomized, dou ...... e to severe atopic dermatitis.
@nl
prefLabel
A multicentre, randomized, dou ...... e to severe atopic dermatitis.
@en
A multicentre, randomized, dou ...... e to severe atopic dermatitis.
@nl
P2093
P2860
P1476
A multicentre, randomized, dou ...... e to severe atopic dermatitis.
@en
P2093
C Groenhoej Larsen
European Tacrolimus Ointment Study Group
F Cambazard
J P Ortonne
R Fölster-Holst
P2860
P304
P356
10.1111/J.1365-2133.2005.06592.X
P407
P577
2005-06-01T00:00:00Z